5 Merger Arb Plays Added to Havens Advisors’ Portfolio in Q2

Page 2 of 2

#3. LinkedIn Corp (NYSE:LNKD)

– Shares owned by Havens Advisors LLC as of June 30: 32,000

– Value of Havens Advisors LLC’s holding as of June 30: $6.06 Million

The successful female-run hedge fund also initiated a new position in LinkedIn Corp (NYSE:LNKD) during the three months that ended June 30, which was comprised of 32,000 shares. The new position was worth $6.06 million at the end of June and made up 4.6% of the fund’s entire portfolio. In mid-June, Microsoft Corporation (NASDAQ:MSFT) announced it was acquiring the professional social network company in an all-cash transaction valued at $26.2 billion. This is by far Microsoft’s largest acquisition ever, with some investors and analysts being worried that deal may not be successful given the tech giant’s disappointing history with acquisitions. However, there appears to be real synergy between the two companies, particularly between Microsoft’s Office productivity suite and LinkedIn’s database of more than 400 million professional profiles. Under the definitive merger agreement, LinkedIn shareholders will receive $196 per share in cash at closing. Alex Snow’s Lansdowne Partners had 1.27 million shares of LinkedIn Corp (NYSE:LNKD) among its holdings at the end of the first quarter.

Follow Linkedin Corp (NYSE:LNKD)

#2. St. Jude Medical Inc. (NYSE:STJ)

– Shares owned by Havens Advisors LLC as of June 30: 96,200

– Value of Havens Advisors LLC’s holding as of June 30: $7.50 Million

Havens Advisors LLC snatched up a new 96,200-share stake in St. Jude Medical Inc. (NYSE:STJ) during the second quarter of 2016, which represented the firm’s fourth-largest equity holding at the end June. The stake was valued at $7.50 million on June 30 and constituted 5.7% of the hedge fund’s portfolio. In late April, Abbott Laboratories (NYSE:ABT) announced it had agreed to purchase medical-products maker St. Jude Medical for $25 billion, representing the largest health-care merger thus far in 2016. Under the terms of the freshly-inked agreement, St. Jude Medial shareholders will receive $46.75 in cash and 0.8708 shares of Abbott. The deal brings together two manufacturers of devices for cardiovascular disease, thus creating a premier medical device leader with top positions in cardiovascular markets. The transaction, subject to the approval of St. Jude Medial shareholders and regulators, is anticipated to close in the fourth quarter. Ken Fisher’s Fisher Asset Management cut its stake in St. Jude Medical Inc. (NYSE:STJ) by 9% during the June quarter to 237,317 shares.

Follow St Jude Medical Llc (NYSE:STJ)

#1. Medivation Inc. (NASDAQ:MDVN)

– Shares owned by Havens Advisors LLC as of June 30: 183,500

– Value of Havens Advisors LLC’s holding as of June 30: $11.07 Million

The New York-based hedge fund firm also acquired a new stake of 183,500 shares of Medivation Inc. (NASDAQ:MDVN) during the June quarter, which was worth $11.07 million at the end of the period. The Medivation-stake was the second-largest position in the hedge fund’s portfolio, accounting for 8.4% of its entire value. Although the U.S cancer drug company has not reached a merger agreement just yet, the San Francisco-based company is currently in merger talks with several drugs firms, including Sanofi SA (ADR) (NYSE:SNY). Just recently, Medivation rejected the French company’s offer of $58 per share and an additional $3 per share bonus related to sales of cancer drug Talazoparib. This comes after Medivation rejected Sanofi’s $52.50 per share offer in April, prompting the French drug maker to embark on a campaign to overhaul the target’s boardroom. Talazoparib is under development for the treatment of breast cancer. Fred Knoll’s Knoll Capital Management owned 4.40 million shares of Medivation Inc. (NASDAQ:MDVN) on March 31.

Follow Medivation Inc. (NASDAQ:MDVN)

Disclosure: None

Page 2 of 2